TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01034202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC126-0083
Description: One of five dose levels administered subcutaneously (under the skin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC126-0083
Description: One of five dose levels administered subcutaneously (under the skin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norditropin® SimpleXx®
Description: One of two dose levels, followed by NNC126-0083, administered subcutaneously (under the skin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norditropin® SimpleXx®
Description: One of two dose levels, followed by NNC126-0083, administered subcutaneously (under the skin)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo comparator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo comparator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC126-0083
Description: One of three dose levels administered subcutaneously (under the skin)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Norditropin® SimpleXx®
Description: One of two dose levels, followed by placebo, administered subcutaneously (under the skin)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Norditropin® SimpleXx®
Description: One of two dose levels, followed by placebo, administered subcutaneously (under the skin)
Study: NCT03292666

Intervention type: DRUG
Intervention: Oral Anticoagulant
Description: Oral anticoagulants used to treat or prevent venous thromboembolism
Study: NCT04381728

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Womed Leaf
Description: Womed Leaf uterine film will be inserted immediately after the myomectomy, following per-operative hysterometry.
Study: NCT00729664

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-PDL-1 antibody
Description: Solution, Intravenous, 0.1 mg/kg, Every 14 days, 3 doses per each cycle of 42 days, 16 cycles/48 doses depending on response

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-PDL-1 antibody
Description: Solution, Intravenous, 0.3 mg/kg, Every 14 days, 3 doses per each cycle of 42 days, 16 cycles/48 doses depending on response

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-PDL-1 antibody
Description: Solution, Intravenous, 1 mg/kg, Every 14 days, 3 doses per each cycle of 42 days, 16 cycles/48 doses depending on response

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-PDL-1 antibody
Description: Solution, Intravenous, 3 mg/kg, Every 14 days, 3 doses per each cycle of 42 days, 16 cycles/48 doses depending on response

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-PDL-1 antibody
Description: Solution, Intravenous, 10 mg/kg, Every 14 days, 3 doses per each cycle of 42 days, 16 cycles/48 doses depending on response
Study: NCT00505219

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ixmyelocel-T
Description: Core decompression of the femoral head to remove necrotic tissue with Ixmyelocel-T given to treatment arm only.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Only
Description: Core decompression of the femoral head to remove necrotic tissue
Study: NCT00756964

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rasburicase
Description: Rasburicase (Dose: 7.5mg in 50ml of normal saline administered over 30 minutes) or identical placebo will be administered as an (dosage form)intravenous infusion preoperatively.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo drug (color-coded to appear identical to study drug) administered as an (dosage form) intravenous infusion preoperatively.
Study: NCT02604043

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pH monitoring
Description: After endotracheal intubation, the impedence/pH probe will be placed under indirect visualization using a McGrath MAC video laryngoscope directly above the vocal cords. The sensor will remain in place for the duration of the surgery or for 24 hours in ICU patients. At that time, the device will be manually removed by a member of the study staff.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: accelerometer monitoring
Description: Patient position will be continuously monitored with the accelerometer for the duration of the pH monitoring period.
Study: NCT01092234

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional ward
Description: provision of care in a traditional unit/ward.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Organizational change
Description: Observational unit (new organizational unit) for organizing in-hospital care
Study: NCT01571219

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: CT-P13(3mg/kg) administered as a 2-hour IV infusion per dose co-administered with methotrexate between 12.5 to 25 mg/week, oral or parenteral dose (dose and route must be maintained from Study CT-P13 3.1 and be maintained from the beginning to the end of the extension study) and folic acid(≥5mg/week, oral dose)
Study: NCT06047730

Intervention type: PROCEDURE
Intervention: operation ways
Description: nothing

Intervention type: PROCEDURE
Intervention: operation ways
Description: nothing

Intervention type: PROCEDURE
Intervention: operation ways
Description: nothing
Study: NCT03919552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel,Carboplatin
Description: Patients receive docetaxel (75mg/m2 on day 1), carboplatin (AUC 4 on day 1) every three weeks for two cycles before the radiotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel,Cisplatin
Description: Patients receive docetaxel (75mg/m2 on day 1), cisplatin (75mg/m2 on day 1) every three weeks for two cycles before the radiotherapy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Carboplatin-based concurrent chemoradiotherapy
Description: Patients receive radical radiotherapy and carboplatin (AUC 5) every three weeks for three cycles during radiotherapy.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin-based concurrent chemoradiotherapy
Description: Patients receive radical radiotherapy and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy.
Study: NCT01812109

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hutchison Technologies Inspectra StO2 SpotCheck Near-Infrared Spectroscopy
Description: Device: Near-Infrared Spectroscopy Transscrotal NIRS is a series of 6 transcutaneous scrotal measurements, 3 on both left/right. Each measurement is completely non-invasive, painless and takes \~15 seconds each. Thus, no sedation or supplemental analgesia is needed for NIRS. The NIRS probe will be placed on the anterior, lateral and posterior scrotum on the left/right sides, immediately overlying and parallel to the long axis of the testis but on the skin to obtain the 6 total measurements. The unaffected testis will serve as the patient's own control. Study coordinators will be performing the ER transscrotal NIRS testing. For uniformity, all will be trained for testicular probe placement methods. NIRS will not delay the gray scale/color Doppler testicular US or surgery.
Study: NCT03137160

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Injection
Study: NCT01737632

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multidimensional Family Therapy (MDFT)
Description: MDFT assesses and intervenes in five domains: 1) Interventions with the adolescent, 2) interventions with the parent, 3) interventions to improve the parent-adolescent relationship, 4) interventions with other family members, and 5) interventions with external systems.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Adolescent Residential Treatment
Description: The Adolescent Treatment Program targets the adolescent's abuse or dependency on chemicals while simultaneously treating the comorbid symptomatology found in dual diagnosed patients. These goals are accomplished by using four primary forms of intervention: (1) Chemical Education; (2) Group, Individual and Family Counseling; (3) Twelve Step Work; and 4) Psychotropic Medication for Clinical Symptomatology Comorbid with Substance Abuse.
Study: NCT03956979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JM-010 group A
Description: JM-010 fixed combination drug (Group A) + Placebo 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JM-010 group B
Description: JM-010 fixed combination drug (Group B) + Placebo 1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo 1 + Placebo 2
Study: NCT00779935

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Remicade
Description: Remicade will be given at Weeks 0, 2, and 6 and then every 8 weeks up to Week 54.
Study: NCT04622579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide combined with rituximab
Description: lenalidomide and rituximab are dilivered as described, parameters concerning efficacy and safety are also obtained.
Study: NCT03212105

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 60 Second Video
Description: The mindfulness intervention will be a video-flash found at http://www.pixelthoughts.co. In this exercise patients are asked to write down a concern or worry, and watch it get put into perspective within a 60 seconds time frame.
Study: NCT03960918

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: aerobic exercise therapy
Description: aerobic exercise therapy: All enrolled subjects will perform a CPET before the training initiation. After CPET, the patients in the experimental group need to perform an additional bicycle training program with the intensity of 60 % maximal workload in the previous CPET (five days per week, for four weeks with a total of 20 times).
Study: NCT02088528

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aurolab glaucoma drainage device
Description: Patients undergoing surgery will receive an implant

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trabeculectomy with mitomycin-c
Description: Trabeculectomy surgery augmented by application of mitomycin C (0.4 mg/ml) to the sclera in the region of the trabeculectomy site for a period of exactly 3 minutes.
Study: NCT03325647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Cypionate 200 Milligram/Milliliter Injectable Solution
Description: Subjects in one arm will be randomized to receive testosterone cypionate 200 mg/ml intramuscularly every 4 weeks for a total of three doses after visit 1, and receive placebo injectable saline for the same duration starting at visit 2. Subjects in the other arm will be randomized to receive placebo injectable saline every 4 weeks for a total of 3 doses after visit 1, and testosterone cypionate 200 mg/ml intramuscularly for the same duration starting at visit 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Cypionate 200 Milligram/Milliliter Injectable Solution
Description: Subjects in one arm will be randomized to receive testosterone cypionate 200 mg/ml intramuscularly every 4 weeks for a total of three doses after visit 1, and receive placebo injectable saline for the same duration starting at visit 2. Subjects in the other arm will be randomized to receive placebo injectable saline every 4 weeks for a total of 3 doses after visit 1, and testosterone cypionate 200 mg/ml intramuscularly for the same duration starting at visit 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo injectable saline
Description: Subjects in one arm will be randomized to receive testosterone cypionate 200 mg/ml intramuscularly every 4 weeks for a total of three doses after visit 1, and receive placebo injectable saline for the same duration starting at visit 2. Subjects in the other arm will be randomized to receive placebo injectable saline every 4 weeks for a total of 3 doses after visit 1, and testosterone cypionate 200 mg/ml intramuscularly for the same duration starting at visit 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo injectable saline
Description: Subjects in one arm will be randomized to receive testosterone cypionate 200 mg/ml intramuscularly every 4 weeks for a total of three doses after visit 1, and receive placebo injectable saline for the same duration starting at visit 2. Subjects in the other arm will be randomized to receive placebo injectable saline every 4 weeks for a total of 3 doses after visit 1, and testosterone cypionate 200 mg/ml intramuscularly for the same duration starting at visit 2.
Study: NCT03495193

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training
Description: Exercise training will be performed 3x/week. After 2 sessions, training volume and intensity will progress over the first 4 sessions ramping up the number of sets to increase the volume. The full volume prescription will consist of: 1) 5 movements to improve strength and muscle mass (leg press, knee extension, chest press, overhead press, pull down), 3 sets each of 8-12 repetitions (\~30 total repetitions); 2) trunk exercises to improve postural stability (trunk extension and flexion); 3) 3-4 bodyweight exercises (selected from a menu) to improve power and balance (e.g. step up, squat, jump squat, lunge, side lunge, push-up, assisted pull-up, assisted dip). Bodyweight movements will be modified as necessary to match abilities.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep hygiene
Description: Subjects randomized to the no-exercise group will receive a handout with tips for improving sleep. Additionally, study staff will provide the title page for a book on sleep relaxation techniques that is recommended for persons with sleeping difficulty. Dr. Amara will review the sleep tips with the subjects and make recommendations for improving current sleep habits. Subjects will be contacted by telephone every 4 weeks during the 16-week intervention period.
Study: NCT04312659

Intervention type: DRUG
Intervention: Infliximab
Description: Participants will be observed who were treated with Infliximab.
Study: NCT03619499

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: non invasive ventilation
Description: patients who will fulfill the criteria of severe bronchiolitis will be connected to non invasive ventilation including continuous positive airway pressure via nasal prongs or nasal mask. Mode of ventilation, inspired oxygen levels, oxygen saturation, respiratory rate, and blood gas values from arterial samples prior to and after 2 and 4 hrs of ventilation or nearest time, will be documented.
Study: NCT03988725

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin E
Description: Vitamin E 800 IU once daily
Study: NCT01357356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SER120 (750 ng/day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SER120 (1000 ng/day)
Description: SER120 (1000 ng/day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SER120 (1500 ng/day)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00352079

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BCG vaccine
Description: Intravesical BCG:~Induction:~q weekly x 6 (cycle 1)~Maintenance:~q weekly x 3 at 3, 6, 12, 18, 24, 30, 36 months post- 2 randomization (cycles 2 - 8)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BCG vaccine
Description: Intravesical BCG:~Induction:~q weekly x 6 (cycle 1)~Maintenance:~q weekly x 3 at 3, 6, 12, 18, 24, 30, 36 months post- 2 randomization (cycles 2 - 8)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gefitinib
Description: Iressa® 250 mg PO Daily for 12 weeks starting on day 1 of each cycle of intravesical BCG therapy (cycles 1 - 8)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Description: Each cycle and at 3 and 6 months after treatment discontinuation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Description: Each cycle and at 3 and 6 months after treatment discontinuation
Study: NCT01097356

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotic drinkers
Description: HPV+, LSIL patients in this arm will drink the probiotic study drink for a period of 6 months
Study: NCT02647554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ulinastatin
Description: ulinastatin 400,000 IU every 8 hours for 10 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo every 8 hours for 10 days
Study: NCT02804269

Intervention type: OTHER
Intervention: Cardiovascular Magnetic Resonance
Description: For the evaluation of heart function and structure of the cardiovascular system.

Intervention type: OTHER
Intervention: Cardiovascular Magnetic Resonance
Description: For the evaluation of heart function and structure of the cardiovascular system.

Intervention type: OTHER
Intervention: Cardiovascular Magnetic Resonance
Description: For the evaluation of heart function and structure of the cardiovascular system.

Intervention type: OTHER
Intervention: Cardiovascular Magnetic Resonance
Description: For the evaluation of heart function and structure of the cardiovascular system.

Intervention type: OTHER
Intervention: Cardiovascular Magnetic Resonance
Description: For the evaluation of heart function and structure of the cardiovascular system.

Intervention type: OTHER
Intervention: Fatmass measurement
Description: It utilizes a scale machine to measure the body fat and skeletal muscle percentage

Intervention type: OTHER
Intervention: Fatmass measurement
Description: It utilizes a scale machine to measure the body fat and skeletal muscle percentage

Intervention type: OTHER
Intervention: Fatmass measurement
Description: It utilizes a scale machine to measure the body fat and skeletal muscle percentage

Intervention type: OTHER
Intervention: Fatmass measurement
Description: It utilizes a scale machine to measure the body fat and skeletal muscle percentage

Intervention type: OTHER
Intervention: Fatmass measurement
Description: It utilizes a scale machine to measure the body fat and skeletal muscle percentage
Study: NCT03476915

Intervention type: OTHER
Intervention: ultrasound examination of the hip joint
Description: US examination by US machine , Midray model DP-2200 made in China , with a high frequency (5-10 MHZ) linear transducer using the previously described Graf method for assessment of both hip joints.
Study: NCT02880072

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: phosphate orally
Description: 4 different preparations of phosphate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: phosphate orally
Description: 4 different preparations of phosphate
Study: NCT05175079

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupressure band
Description: acupressure band apply to P6 (nei guan) point which located three fingers below the skin wrinkles of the anterior wrist.~Acupressure band wear 3 times daily before breakfast, lunch and dinner for at least 10 minutes

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard treatment hospital protocol
Description: Intravenous metaclopromide 10mg PRN Intravenous fluids as per protocol
Study: NCT02038478

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor Stem Cell Transplantation
Description: One day after they complete their radiation and Campath-1H treatments and have begun their Sirolimus, the donor blood stem cells described above are transfused through the central line. This process takes approximately 30 minutes to 2 hours and is normally completely without side effects.
Study: NCT02297906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: Non-steroidal anti-inflammatory drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: Non-steroidal anti-inflammatory drug
Study: NCT03776851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erythropoietin
Description: erythropoietin 50 International Units (IU) per kilogram three times weekly by subcutaneous route
Study: NCT03105115

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fentanyl
Description: intrathecal fentanyl will be added as adjuvant for spinal anesthesia using heavy bupivacaine, while dexmedetomidine will be infused intravenously during operation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivacaine only
Description: heavy bupivacaine will be injected intrathecally during spinal anesthesia, without fentanyl, while dexmedetomidine will be infused intravenously during operation
Study: NCT02615327

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 8 g Polydextrose
Description: 8g of Polydextrose

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 12 g Polydextrose
Description: 12 g of Polydextrose

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 16 g Polydextrose
Description: 16 g of Polydextrose

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0 g of Polydextrose
Study: NCT01963819

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endometrial biopsy
Description: The endometrial biopsy will be done in the luteal phase (cycle day 18-22) prior to the treatment cycle (antagonist)
Study: NCT00732329

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Occupational Therapy
Description: optimized home Based Occupational Therapy including:~* diagnostic assessment~* patient-centered definition of targets involving the care giver~* occupational therapy
Study: NCT00600288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diquafosol tetrasodium Ophthalmic Solution, 2%
Description: 1-2 drops administered in each eye 4 times a day for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Non-preserved saline solution (Placebo)
Description: 1-2 drops administered in each eye 4 times a day for 6 weeks
Study: NCT00782236

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Graft Material
Description: After screening and enrollment, subjects will undergo tooth extraction of a single tooth with placement of Straumann Bone Ceramic or Freeze Dried Allograft Bone (FDBA) with a resorbable collagen membrane (Bio-Gide) for preservation of the alveolar ridge following tooth extraction. Following 6 months of healing, a core of bone will be taken from the surgical site and a dental implant will be placed. The subjects will then be followed for 12 months following dental implant placement.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Graft Material
Description: After screening and enrollment, subjects will undergo tooth extraction of a single tooth with placement of Straumann Bone Ceramic or Freeze Dried Allograft Bone (FDBA) with a resorbable collagen membrane (Bio-Gide) for preservation of the alveolar ridge following tooth extraction. Following 6 months of healing, a core of bone will be taken from the surgical site and a dental implant will be placed. The subjects will then be followed for 12 months following dental implant placement.